ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.620
-0.050 (-1.87%)
Dec 20, 2024, 4:00 PM EST - Market closed
ImmunityBio Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Net Income | -587.79 | -583.2 | -416.57 | -346.79 | -221.85 | -157.78 | Upgrade
|
| Depreciation & Amortization | 17.98 | 18.51 | 18.26 | 14.24 | 12.74 | 14.04 | Upgrade
|
| Other Amortization | 24.7 | 42.4 | 16.28 | 0.06 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.89 | 0.89 | 2.01 | - | 10.66 | 1.59 | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.33 | 1.45 | 5.51 | 5.02 | -0.68 | 0.32 | Upgrade
|
| Stock-Based Compensation | 38.17 | 49.16 | 40.18 | 57.18 | 2.19 | 3.42 | Upgrade
|
| Other Operating Activities | 119.35 | 100.05 | 4.82 | 14.98 | 8.86 | 1.93 | Upgrade
|
| Change in Accounts Payable | -2.83 | -6.48 | 8 | -3.72 | 2.57 | 1.19 | Upgrade
|
| Change in Other Net Operating Assets | -25.37 | 10.45 | -16 | -15.4 | 13.79 | -16.82 | Upgrade
|
| Operating Cash Flow | -421.36 | -366.76 | -337.51 | -274.42 | -171.72 | -152.11 | Upgrade
|
| Capital Expenditures | -12.73 | -30.58 | -78.16 | -33.56 | -1.67 | -4.29 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 20.5 | - | 0.2 | Upgrade
|
| Divestitures | - | - | - | - | - | -2.5 | Upgrade
|
| Sale (Purchase) of Intangibles | - | - | -21.23 | - | - | - | Upgrade
|
| Investment in Securities | -7.1 | 0.11 | 126.69 | -71.82 | -18.14 | 25.14 | Upgrade
|
| Investing Cash Flow | -19.83 | -30.47 | 27.3 | -84.89 | -19.81 | 18.55 | Upgrade
|
| Long-Term Debt Issued | - | 451.46 | 174.13 | 338.5 | 63.7 | 47.67 | Upgrade
|
| Long-Term Debt Repaid | - | -0.08 | -0.06 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | 289.64 | 451.39 | 174.07 | 338.5 | 63.7 | 47.67 | Upgrade
|
| Issuance of Common Stock | 91.83 | 110.4 | 60.5 | 169.99 | 87.48 | 69.24 | Upgrade
|
| Repurchase of Common Stock | -6.22 | -3.44 | -0.62 | -4.06 | -0.5 | -2.5 | Upgrade
|
| Other Financing Activities | - | - | -0.34 | 1.02 | - | -0.13 | Upgrade
|
| Financing Cash Flow | 375.24 | 558.34 | 233.61 | 505.44 | 150.68 | 114.28 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.04 | -0.29 | 0.28 | 0.05 | -0.03 | -0.02 | Upgrade
|
| Net Cash Flow | -66 | 160.82 | -76.32 | 146.19 | -40.89 | -19.3 | Upgrade
|
| Free Cash Flow | -434.1 | -397.34 | -415.67 | -307.98 | -173.39 | -156.4 | Upgrade
|
| Free Cash Flow Margin | -5920.55% | -63881.19% | -173196.25% | -32974.52% | -28660.00% | -7102.45% | Upgrade
|
| Free Cash Flow Per Share | -0.64 | -0.78 | -1.04 | -0.79 | -0.46 | -0.43 | Upgrade
|
| Cash Interest Paid | 115.74 | 77.19 | 35.44 | 2.11 | 0.04 | 0.02 | Upgrade
|
| Cash Income Tax Paid | 0.02 | 0.01 | 0 | 0.01 | 0.01 | 0 | Upgrade
|
| Levered Free Cash Flow | -288.76 | -234.66 | -299.03 | -170.3 | -94.55 | -108.15 | Upgrade
|
| Unlevered Free Cash Flow | -220.41 | -196.31 | -275.62 | -161.08 | -88.88 | -104.45 | Upgrade
|
| Change in Net Working Capital | 39.27 | 7.55 | 15.5 | 0.55 | -23.28 | 19.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.